L Nogueira1, M Sebbag, C Vincent, M Arnaud, B Fournié, A Cantagrel, M Jolivet, G Serre. 1. Department of Biology and Pathology of the Cell, Institut National de la Santé et de la Recherche Médicale (CJF 96-02), Toulouse-Purpan School of Medicine, University of Toulouse III (IFR Claude de Préval, INSERM-CNRS-UPS - CHU), France.
Abstract
OBJECTIVE: To develop a standardisable enzyme linked immunosorbent assay (ELISA), using human filaggrin, for detection of antifilaggrin autoantibodies in rheumatoid arthritis (RA). To compare the diagnostic performance of the ELISA with those of reference tests: "antikeratin antibodies" ("AKA"), and antibodies to human epidermis filaggrin detected by immunoblotting (AhFA-IB). METHODS: Two ELISAs were developed using either affinity purified neutral-acidic human epidermis filaggrin (AhFA-ELISA-pur) or a recombinant human filaggrin deiminated in vitro (AhFA-ELISA-rec) as immunosorbent. Antifilaggrin autoantibodies were assayed in 714 serum samples from patients with well characterised rheumatic diseases, including 241 RA and 473 other rheumatic diseases, using the two ELISAs. "AKA" and AhFA-IB tests were carried out in the same series of patients. The diagnostic performance of the four tests was compared and their relationships analysed. RESULTS: The titres of "AKA", AhFA-IB, and the AhFA-ELISAs correlated strongly with each other. The diagnostic sensitivity of the AhFA-ELISA-rec, which was better than that of AhFA-ELISA-pur, was 0.52 for a specificity of 0.95. This performance was similar to those of "AKA" or AhFA-IB. However, combining AhFA-ELISA-rec with AhFA-IB led to a diagnostic sensitivity of 0.55 for a specificity of 0.99. CONCLUSION: A simple and easily standardisable ELISA for detection of antifilaggrin autoantibodies was developed and validated on a large series of patients using a citrullinated recombinant human filaggrin. The diagnostic performance of the test was similar to that of the "AKA" and AhFA-IB. Nevertheless, combining the AhFA-ELISA-rec with one of the other tests clearly enhanced the performance.
OBJECTIVE: To develop a standardisable enzyme linked immunosorbent assay (ELISA), using humanfilaggrin, for detection of antifilaggrin autoantibodies in rheumatoid arthritis (RA). To compare the diagnostic performance of the ELISA with those of reference tests: "antikeratin antibodies" ("AKA"), and antibodies to human epidermis filaggrin detected by immunoblotting (AhFA-IB). METHODS: Two ELISAs were developed using either affinity purified neutral-acidic human epidermis filaggrin (AhFA-ELISA-pur) or a recombinant humanfilaggrin deiminated in vitro (AhFA-ELISA-rec) as immunosorbent. Antifilaggrin autoantibodies were assayed in 714 serum samples from patients with well characterised rheumatic diseases, including 241 RA and 473 other rheumatic diseases, using the two ELISAs. "AKA" and AhFA-IB tests were carried out in the same series of patients. The diagnostic performance of the four tests was compared and their relationships analysed. RESULTS: The titres of "AKA", AhFA-IB, and the AhFA-ELISAs correlated strongly with each other. The diagnostic sensitivity of the AhFA-ELISA-rec, which was better than that of AhFA-ELISA-pur, was 0.52 for a specificity of 0.95. This performance was similar to those of "AKA" or AhFA-IB. However, combining AhFA-ELISA-rec with AhFA-IB led to a diagnostic sensitivity of 0.55 for a specificity of 0.99. CONCLUSION: A simple and easily standardisable ELISA for detection of antifilaggrin autoantibodies was developed and validated on a large series of patients using a citrullinated recombinant humanfilaggrin. The diagnostic performance of the test was similar to that of the "AKA" and AhFA-IB. Nevertheless, combining the AhFA-ELISA-rec with one of the other tests clearly enhanced the performance.
Authors: C Masson-Bessière; M Sebbag; E Girbal-Neuhauser; L Nogueira; C Vincent; T Senshu; G Serre Journal: J Immunol Date: 2001-03-15 Impact factor: 5.422
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: C Masson-Bessière; M Sebbag; J J Durieux; L Nogueira; C Vincent; E Girbal-Neuhauser; R Durroux; A Cantagrel; G Serre Journal: Clin Exp Immunol Date: 2000-03 Impact factor: 4.330
Authors: S Muñoz-Fernández; R Alvarez-Doforno; J M González-Tarrio; A Balsa; P Richi; G Fontán; J Gijón-Baños; E Martin-Mola Journal: J Rheumatol Date: 1999-12 Impact factor: 4.666
Authors: R Goldbach-Mansky; J Lee; A McCoy; J Hoxworth; C Yarboro; J S Smolen; G Steiner; A Rosen; C Zhang; H A Ménard; Z J Zhou; T Palosuo; W J Van Venrooij ; R L Wilder; J H Klippel; H R Schumacher; H S El-Gabalawy Journal: Arthritis Res Date: 2000-03-31
Authors: O Vittecoq; B Incaurgarat; F Jouen-Beades; J Legoedec; O Letourneur; D Rolland; G Gervasi; J F Ménard; A Gayet; P Fardellone; A Daragon; M Jolivet; X le Loët; F Tron Journal: Clin Exp Immunol Date: 2004-01 Impact factor: 4.330
Authors: Katerina A Drouvalakis; Sarunya Bangsaruntip; Wolfgang Hueber; Leland G Kozar; Paul J Utz; Hongjie Dai Journal: Biosens Bioelectron Date: 2007-12-14 Impact factor: 10.618